Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sertraline versus nortriptyline versus antispasmodic treatment for anxiety and gastrointestinal symptoms in irritable bowel syndrome
IRCT20190618043934N13Phase 3Completed
- Sponsor
- Vice Chancellor for Research, Birjand University of Medical Sciences
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sertraline, nortriptyline and mebeverine in irritable bowel syndrome (IBS) (3 arms), sponsored by Vice Chancellor for Research, Birjand University of Medical Sciences. Primary endpoints: Anxiety and Clinical gastrointestinal symptoms. Started Aug 2021; status: completed.
02
Drugs
sertralinenortriptylinemebeverine
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on IRCT20190618043934N13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190618043934N13.